CAR T-Cell Therapy | Clinical

Novel Engineered CAR T Cells Show Early Promise in CD19+ B-Cell Malignancies

October 23, 2020

Chimeric antigen receptor T-cell therapy with the novel agent CTX110 showed promising early efficacy and safety as treatment of patients with relapsed or refractory CD19-positive B-cell malignancies who were treated in the phase 1 CARBON clinical trial.

CAR T-Cell Data Call for New Strategies in Treatment of Multiple Myeloma

September 15, 2020

During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.

Early Study Shows Feasibility of Single Vector Multiplexed shRNA for CAR T Cells

September 04, 2020

In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.